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O riginal A rticle

An investigation of human beta-defensins and cathelicidin expression in
patients with pterygium
Uma investigação da expressão de beta-defensinas humanas e de catelidicina em pacientes com pterígio
Remzi Karadag1,2, Nurettin Bayram3, Serpil Oguztuzun4, Huseyin Bayramlar1, Busra Bozer5, Gulcin Simsek6, Christopher J. Rapuano2

ABSTRACT

RESUMO

Purpose: To investigate human beta-defensins (HBDs) and cathelicidin LL-37
(LL-37) expressions in patients with pterygium.
Methods: In this retrospective consecutive case series, 26 pterygium specimens
and 15 normal conjunctival specimens of 15 control subjects were inv estigated.
Expressions of HBD-1, HBD-2, HBD-3, and LL-37 were assessed using immuno
histochemical staining. A brown color in the cytoplasm and/or nuclei of epithelial cells indicated positive staining for HBDs and LL-37. For each antibody,
the intensity of the reaction (negative [-], weak [1+], moderate [2+], or strong
[3+]) was determined to describe the immunoreactions.
Results: The median age was 52 years in both groups. There were no significant
differences in age and sex between the groups (p=0.583, p=0.355, respectively).
Of the 26 pterygium specimens, 15 (57.7%) (14 weak, 1 moderate staining) showed
HBD-2 expression, which was not observed in any of the control specimens. One
(3.8%) pterygium and one (6.7%) control specimen demonstrated weak staining
for HBD-3. HBD-2 expression was significantly higher in the pterygium specimens
than in the controls (p=0.002). None of the tissue specimens had positive staining
for HBD-1 or LL-37 in either group (both; p=1.00).
Conclusions: HBD-2 expression was higher in pterygium specimens than in the
controls. HBD-2 expression that might be stimulated by inflammatory cytokines
may be related to inflammation and fibrovascular proliferation and may play a
role in pterygium pathogenesis.

Objetivo: Investigar as expressões beta defensinas humanas (HBD) e catelicidina
em pacientes com pterígio.
Métodos: Nesta série de casos retrospectivos consecutivos, 26 espécimes de pterígio e
15 espécimes conjuntivais normais de 15 indivíduos controle foram investigados.
As expressões de HBD-1, HBD-2, HBD-3 e catelicidina (LL-37) foram avaliadas por
coloração imuno-histoquímica. Uma cor castanha no citoplasma ou nos núcleos
de células epiteliais foi definida como coloração positiva para HBDs e LL-37. Para
cada anticorpo foi determinada a intensidade da reação (negativo [-], fraco [1+],
moderado [2+] ou forte [3+]) para descrever as imunoreações.
Resultados: A idade média foi de 52 anos em ambos os grupos. Não houve diferença significativa entre os grupos em termos de idade e sexo (p=0,583, p=0,355,
respectivamente). Das 26 amostras de pterígio, 15 (57,7%) (14 fracas e 1 moderada)
demonstraram a expressão de HBD-2 enquanto não foi encontrada em nenhum dos
espécimes de controlo. Um dos pterígios (3,8%) e um dos espécimes de controlo (6,7%)
demonstraram fraca coloração para HBD-3. A expressão de HBD-2 foi significati
vamente maior nos espécimes de pterígio do que nos controles (p=0,002). Nenhum
dos espécimes de tecido apresentou coloração positiva para HBD-1 ou LL-37 em
ambos os grupos (ambos p=1,00).
Conclusão: Encontramos aumento da expressão de HBD-2 em espécimes de pterígio
em relação aos controles. A expressão de HBD-2 que pode ser estimulada por citocinas
inflamatórias pode estar relacionada com inflamação e proliferação fibrovascular e
pode desempenhar um papel na patogênese do pterígio.

Keywords: Cathelicidins; Beta-defensins; Immunohistochemical; Inflammation;
Pterygium/pathology

Descritores: Catelicidinas; Beta defensinas; Imunohistoquímica; Inflamação; Pte
rígio/patologia

INTRODUCTION
Pterygia develop from the growth of fibrovascular tissue of bulbar
conjunctiva into the interpalpebral area of the cornea. Although the
pathogenesis is not completely understood, oxidative stress, immunogenic mechanisms, anti-apoptosis, extracellular matrix remodeling, angiogenesis, viral infections, and genetic factors are considered
to be contributing factors. Epidemiological studies have shown that
chronic ultraviolet exposure has a major role in pterygium pathogenesis(1). Ultimately, chronic inflammation due to some or all of the
above factors probably causes fibrovascular proliferation. Cytokines,
growth factors, stem cell factors, and pro-angiogenic factors may
all have a role in inflammation and fibrovascular proliferation of
pathogenesis of pterygium(1). It has been shown that the expression

of human alpha-defensin, which is an antimicrobial peptide (AMP),
is increased in the tears of patients with pterygia because of fibrovascular proliferation or associated inflammation(2). In addition, it has
been reported that some AMPs may be stimulated by proinflammatory cytokines, such as interleukin (IL)-1 alpha, IL-1 beta, and tumor
necrosis factor-alpha(3,4).
AMPs provide one of the defense mechanisms that are part of
the innate immune response against exogenous pathogens. AMPs
are divided into two major groups: defensins and cathelicidins. Human defensins are also divided into two groups: alpha and beta(5).
Human beta-defensins (HBD) have four subgroups (1 to 4) and are
primarily expressed in epithelial tissues. However, HBD-1 and -2 are
also present in immune cells, such as monocytes, macrophages, and
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dendritic cells(6). It has been shown that the expressions of HBD-2
and -3 are stimulated by some cytokines(3-7). Although HBD-1 and -3
have been found in healthy corneal and conjunctival epithelial cells,
HBD-2 expression has not been found or is present only at very low
levels in normal cells. On the other hand, HBD-2 expression has been
found to be increased in inflammatory cells related to dry-eye syndrome(3,4). Cathelicidins are the second group of AMPs. In humans the
group is represented only by cathelicidin LL-37 (LL-37), a molecule
that is expressed in corneal and conjunctival epithelial cells(8,9). This
peptide has also been found to be expressed after corneal epithelial
trauma and in response to some bacterial infections(10,11).
In previous studies, increased human alpha-defensin has been
found in the tears of patients with pterygia(2), and increased expression of HBD-2 has been found in conjunctival impression
cytological specimens of patients with dry-eye syndrome(3). To our
knowledge, this is the first report of AMP expression in pterygium
specimens in the literature. In this study, our aim was to investigate
the expression of HBDs and cathelicidin in pterygium specimens,
and whether their presence correlated with disease severity.

primary antibodies diluted 1:300 for anti-HBD-3, 1:400 for anti-HBD-2,
1:350 for anti-HBD-1, and 1:50 for anti-LL-37 in TBS at 4°C overnight.
Anti-HBD-1 (PA1450) was obtained from Boster Bio., Pleasanton, CA,
United States., anti-HBD-2 (sc-59494) was from Santa Cruz Inc., Santa
Cruz, CA, USA, USA; anti-HBD-3 (NB200-117) was from Novus Biologicals Inc., Littleton, CO, USA; and LL-37 (sc-166770) was from Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA, USA).
After washing in TBS for 15 minutes, the sections were incubated
at RT in biotinylated link antibody (SHP125) (ScyTek Laboratories).
Then, treatment was followed with Streptavidin/HRP complex
(SHP125) (ScyTek Laboratories). Diaminobenzidine was used to vi
sualize peroxidase activity in the tissues. Nuclei were lightly counterstained with hematoxylin, and then the sections were dehydrated
and mounted. Both positive and negative controls were included
in each run. The positive controls consisted of sections of spleen
tissues for LL-37, skin tissues for HBD-3, kidney tissues for HBD-1, and
colon-bladder tissues for HBD-2. TBS was used in place of the primary
antibody for negative controls.

Histopathological evaluation

The multicenter study protocol was carried out in accordance
with the Helsinki Declaration as revised in 2013 and was approved
by the local ethics committee. Written informed consent was obtained
from each subject before surgery. The unused tissue specimens
from our previous study, entitled “GST levels in patients with pterygium”(12), were included in the study. Written informed consent allowing
their tissue to be used for investigational testing was obtained from
each subject before surgery in the previous study(12).

Light microscopy of immunohistochemically stained sections
was performed by a pathologist and a biologist who had no knowledge
of the patients’ clinical information. Distribution, localization, and
characteristics of the immunostaining were recorded. Brown color
in the cytoplasm and/or nuclei of epithelial cells of the epidermis’
basal layer were considered as positive staining. Scoring was also
performed by two observers unaware of the patient data. Scoring
differences between the observers were resolved by consensus.
For each antibody, the intensity of the reaction (negative [-], weak
[1+], moderate [2+], or strong [3+]) was determined to describe the
immunoreactions.

Patient details and specimens

Statistical analysis

Twenty-six pterygium specimens and 15 control specimens
of otherwise healthy patients who were undergoing cataract or
strabismus surgery were included in the study. A detailed ophthalmic examination was performed for each patient, and pterygia
were graded as follows: grade 1, a pterygium that did not prevent
the visibility of episcleral vessels and had only mild inflammatory
clinical signs; grade 2, episcleral vessels that could be partly seen
and presence of moderate inflammatory signs; grade 3, a relatively
thick pterygium that completely prevented the visibility of episcleral vessels and had severe inflammatory signs. Excised pterygium
tissue and 1 x 2-mm specimens of conjunctival tissue from the
control eyes were sent to the Pathology Department for immunohistochemical staining. Unused specimens from the previous study
were prepared again by the staff of the Pathology Department for
immunohistochemical staining.

Statistical analyses were performed by using the SPSS software
version 16 (SPSS Inc., Chicago, IL, USA). Descriptive statistical methods
(mean, standard deviation, median, frequency, ratio, minimum,
maximum), the Mann-Whitney U test and chi-square test were used
in the evaluation of this study’s data. The Wilcoxon signed rank test
was used for unequally distributed data in group comparisons. The
Spearman correlation test was used for evaluating the data between
groups. P values <0.05 were accepted as indicating statistical significance.

METHODS

Inclusion criteria and data collection

Immunohistochemical staining technique
Biopsies were fixed immediately in 10% buffered formalin and
embedded in paraffin blocks. Sections were cut 4-µm thick, and one
section was stained with hematoxylin and eosin to assess the tissue
morphology and tumor score. For immunohistochemistry, endogenous peroxidase activity was blocked by incubating the sections
in 1% hydrogen peroxide (v/v) in methanol for 10 minutes at room
temperature (RT). The sections were subsequently washed in distilled
water for 5 minutes, and antigen retrieval using 0.01M citrate buffer
(pH 6.0) in a domestic pressure cooker was performed for 3 minutes.
The sections were transferred in 0.05M Tris-HCl (pH 7.6) containing
0.15M sodium chloride Tris-buffered saline (TBS). After washing with
water, the sections were incubated at RT for 10 minutes with super
block (SHP125) (ScyTek Laboratories, Logan, UT, USA) to block nonspecific background staining. The sections were then covered with the
278
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RESULTS
Baseline characteristics
This study included 26 primary pterygium tissue specimens
(11 males, 15 females) and 15 control (9 males, 6 females) subjects’
specimens. The pterygium group involved 16 grade 2 and 10 grade
3 pterygium tissue specimens. The median age was 52 years (range,
34-68 years) and 52 years (range, 29-64 years) in the pterygium group
and control group, respectively. There were no significant differences
in age and sex between groups (p=0.583, p=0.355 respectively)
(Table 1).

Immunohistochemical staining results
HBD-1, HBD-2, HBD-3, and LL-37 levels in both groups are shown
in table 1. HBD-2 levels were statistically significantly higher in the
pterygium group than in the control group (p=0.002) (Figure 1).
No significant differences in HBD-1 levels (p=1.00), HBD-3 levels
(p=0.883), and LL-37 levels (p=1.00) were found between the pterygium
group and control group (Table 1 and Figure 1).
There was no statistically significant correlation between the
pterygium grade and HBD-2 level (r=0.090, p=0.661) (Table 2).

K a r a d ag R ,

Table 1. Demographic data and HBD and LL-37 levels in the study and
control groups
Pterygium (n)

Control (n)

P value

52 (34-68)

52 (29-64)

0.583

11/15

9/6

0.355

26

15

1.000

Negative (-)

11

15

0.002

Weak (1+) moderate (2+)

15

0.883

Age median (range) years
Sex (F/M)
HBD-1

Negative (-)
Weak (1+) moderate
(2+)
Strong (3+)

HBD-2

Strong (3+)
HBD-3

Negative (-)

25

14

Weak (1+) moderate (2+)

01

01

26

15

Strong (3+)
LL-37

negative (-)

1.000

weak (1+) moderate (2+)
strong (3+)

D

A

B

C

E

Figure 1. The expressions of human beta-defensins (HBDs) and cathelicidin peptides in
pterygium shown with immunohistochemical staining. A) Negative HBD-2 expression.
B) Negative HBD-1 expression. C) 2 positive HBD-2 peptide expressions. D) Negative
HBD-3 expression; and E) Negative LL-37 expression.

Table 2. Immunohistochemical staining scores
Immunohistochemical staining score

HBD-2 (n)
Pterygium

-

1+

2+

3+

Grade1

0

0

0

0

Grade 2

7

9

0

0

Grade 3

4

5

1

0

Correlation coefficient (r)

0.090

P value

0.661

DISCUSSION
In this study, we determined if the AMPs of HBD-1, HBD-2, HBD-3,
and LL-37 were associated with pterygium pathogenesis. We found
a higher level of HBD-2 in pterygium specimens than in controls, but
HBD-1, HBD-3, and LL-37 levels were similar between the groups.
AMPs serve as a member of the innate immune system on the
ocular surface. These peptides are multifunctional and have nu

et al.

merous properties, including proliferation, cytokine production,
chemotaxis, mast cell stimulation, and histamine release in addition to antimicrobial effects(5). Although HBD-1 was first extracted
from human plasma, it is primarily present in epithelial tissues,
such as airway epithelium, urogenital tissues, nasolacrimal ducts,
and mammary glands. The expressions of HBD-2 and HBD-3 from
various epithelial tissues appear to be stimulated by bacterial products and cytokines. We did not investigate HBD-4 expression(13)
because it has only been reported to be expressed from testis and
epid idymis(4-8). Corneal and conjunctival epithelial cells mainly
express HBD-1 and HBD-3, whereas HBD-2 expression results from
various stimulants. It has been found that HBD-2 expression from
corneal epithelial cells was upregulated as a result of stimulation
from bacterial lipopolysaccharides via tyrosine kinase and p38
mitogen-activated protein kinase activation(14). It has also been
shown that HBD-2 expression was upregulated from corneal(15) and
conjunctival(16) epithelial cells from proinflammatory cytokines,
such as IL-1 and tumor necrosis factor-alpha.
McDermott et al. showed HBD-2 levels to increase in a corneal epithelial wound healing model in an in vitro organ culture
media(17). In two studies on patients with dry-eye syndrome with
an inflammatory component, HBD-2 upregulation was found in
conjunctival impression cytological specimens(16,18). The authors
emphasized that HBD-2 upregulation might be due to the activity
of proinflammatory cytokines(16).
In the other subgroup of AMPs, cathelicidins, only LL-37 exists in
humans and is expressed from corneal and conjunctival epithelial
cells. This peptide expression is a response to corneal epithelial trauma and is found to be elevated in bacterial infections because of
Pseudomonas aeruginosa and Staphylococcus aureus. In addition, it is
the major component of neutrophil granules, as in some defensins,
and may be stimulated by some cytokines(7,19,20,21). Moreover, LL-37
has properties, such as chemotaxis, histamine release from mast
cells, dendritic cell differentiation, and cytokine release, similar to
those of defensins(7).
In previous studies, HBD-1 and HBD-3 expressions were found
mainly in the presence of infections, whereas HBD-2 and LL-37
have been shown to be expressed following injury and inflammation in addition to infection(3,4,7,13-21). In our study, we did not find
any differences in HBD-1, HBD-3, and LL-37 expressions between
pterygium tissue and normal tissue, whereas HBD-2 expression was
significantly higher in pterygium specimens. This finding suggests
that HBD-2 may be associated with the inflammation involved in
pterygium pathogenesis.
Zhou et al. found that human alpha-defensin 1 and 2 expressions
were increased in tears of patients with pterygia. Those authors
stated that the molecules might be related to inflammation or
fibrovascular proliferation in pterygium(2). In our study, we assessed
beta-defensins and cathelicidin as opposed to alpha-defensin. Our
study is the first to compare HBD and cathelicidin expressions in
pterygium specimens with normal tissues.
We found high-level expression of HBD-2, an AMP, in specimens
of pterygium. HBD-2 may have an important role in pterygium pathogenesis. Further studies are necessary to determine if HBD-2 causes
the release of inflammatory cytokines or if inflammatory cytokines
elicit HDB-2 expression.
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